Last reviewed · How we verify
Rifampicin Capsules
Rifampicin inhibits bacterial RNA polymerase, preventing transcription and blocking bacterial protein synthesis.
Rifampicin inhibits bacterial RNA polymerase, preventing transcription and blocking bacterial protein synthesis. Used for Tuberculosis (pulmonary and extrapulmonary), Leprosy, Atypical mycobacterial infections.
At a glance
| Generic name | Rifampicin Capsules |
|---|---|
| Also known as | Rifampicin, rifampin |
| Sponsor | Suzhou Zelgen Biopharmaceuticals Co.,Ltd |
| Drug class | Rifamycin antibiotic |
| Target | Bacterial RNA polymerase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Rifampicin binds to the bacterial RNA polymerase enzyme and inhibits RNA synthesis by blocking the path of the elongating RNA transcript. This mechanism is highly selective for bacterial RNA polymerase and has minimal effect on eukaryotic RNA polymerases, making it effective as an antibiotic. It is bactericidal and works against a broad spectrum of gram-positive and gram-negative bacteria, as well as mycobacteria.
Approved indications
- Tuberculosis (pulmonary and extrapulmonary)
- Leprosy
- Atypical mycobacterial infections
- Prophylaxis of meningococcal meningitis
- Brucellosis
Common side effects
- Hepatotoxicity
- Orange-red discoloration of body fluids
- Gastrointestinal disturbances
- Rash
- Drug interactions (enzyme induction)
Key clinical trials
- Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis (PHASE2)
- A Study Evaluating the Effects of Itraconazole or Rifampin on the Pharmacokinetic Characteristics of Rocbrutinib Tablet (PHASE1)
- A Phase 1/2 Study to Evaluate the Safety, PK and Efficacy of TNP-2092 Administered Via IA Injection in PJI Participants (PHASE1, PHASE2)
- Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis (PHASE4)
- Drug Interaction and Food Effect Study of CS0159 (PHASE1)
- Investigation of Rifampin to Reduce Pedal Amputations for Osteomyelitis in Diabetics (PHASE4)
- Drug-drug Interaction Study of Rifampin and Anaprazole Sodium (PHASE4)
- Clinical Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of HSK31858 in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rifampicin Capsules CI brief — competitive landscape report
- Rifampicin Capsules updates RSS · CI watch RSS
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd portfolio CI